FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ICIAI OWNEDSHID	OMB APP	ROVAL
	OMB Number:	3235-0287

hours per response:

0.5

	OMB APP	ROVAL				
ES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-02				
LO III DEILEI IOIAE OWILLIOIII	Estimated average t	Estimated average burden				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANG

							٠,,													
1. Name and Address of Reporting Person* <u>Greene Barry E</u>					2. Issuer Name and Ticker or Trading Symbol ALNYLAM PHARMACEUTICALS, INC. ALNY									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE					3. Date of Earliest Transaction (Month/Day/Year) 12/23/2019									X Officer (give title Other (specify below) President						
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tabl	e I - Non-I	Deriva	tive S	Secu	urities	Acq	uired, D	isp	osed o	f, or Ber	nefici	ally	Owned					
Date			2. Transac Date Month/Da		Ex if a	A. Deemed xecution Date, any Month/Day/Year)		Code (In:	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)		ed (A) o tr. 3, 4 a	4 and Securitie Benefici		es For ally (D) Following (I)		rm: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	,	Amount	(A) or (D)	Pric	Transa		tion(s)			(11150.4)		
		Ta	able II - De						ired, Dis						Owned			,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Ti	4. Transaction Code (Instr. 8)		n of I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				c	code	v	(A)		Date Exercisable		expiration	Title	Amou or Numb of Share	er						
Performance Stock Option 2017	\$119.13	12/23/2019		I	A ⁽¹⁾		9,999		12/23/2019	C	3/01/2028	Common Stock	9,99	99	\$0.0	19,998	В	D		

Explanation of Responses:

buv)

1. On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019.

> By: /s/ Mary Beth DeLena, 12/26/2019 Attorney-in-Fact For: Barry E. Greene

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.